尔康制药(300267) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss for 2025 between 325 million and 385 million yuan, compared to a loss of 373.37 million yuan in 2024[3] - The net profit after deducting non-recurring gains and losses is projected to be a loss between 331.52 million and 391.52 million yuan, compared to a loss of 368.82 million yuan in the previous year[3] Reasons for Expected Loss - The primary reason for the expected loss is the impairment testing and provision for asset and inventory losses due to insufficient capacity utilization and unfavorable market conditions[5] Business Growth and Revenue - The company's main business has shown steady growth, benefiting from the operation of the lithium ore processing plant in Nigeria, with lithium concentrate revenue exceeding 200 million yuan during the reporting period[6] Cash Flow and Non-Recurring Gains - The cash flow from operating activities has significantly increased compared to the previous year, indicating a strong cash position[6] - Non-recurring gains and losses are expected to contribute approximately 6.52 million yuan to net profit, an increase of 11.07 million yuan compared to the previous year[6] Financial Reporting and Estimates - The financial data in the earnings forecast has not been audited by registered accountants, but there are no significant discrepancies with the auditing firm[4] - The company emphasizes that the earnings forecast is a preliminary estimate and specific financial data will be disclosed in the 2025 annual report[7]